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In vitro transport and satiety of a
beta-lactoglobulin dipeptide and
beta-casomorphin-7 and its metabolites†
Simone Osborne,*a Wei Chen,a Rama Addepalli,a Michelle Colgrave,a Tanoj Singh,b
Cuong Tranc and Li Dayb
Understanding the digestive behaviour and biological activities of dairy proteins may help to develop
model dairy products with targeted health outcomes including increased satiety and healthy weight
maintenance. Caseins and whey proteins constitute over 95% of milk proteins with consumption of these
proteins associated with increased satiety and a decreased prevalence of metabolic disorders. To investi-
gate the in vitro digestive behaviour and satiety of dairy proteins at the intestinal epithelium, the in vitro
transport and hydrolysis of 500–2000 μM β-casomorphin-7 (YPFPGPI or β-CM7) and a β-lactoglobulin
(β-Lg) dipeptide (YL) was measured using Caco-2 cell monolayers grown on transwells as a model of
the intestinal epithelium. Transport of YL was concentration dependent and ranged from 0.37–5.26 ×
10−6 cm s−1, whereas transport of β-CM7 was only detected at 2000 μM and was signiﬁcantly lower at
0.13 × 10−6 cm s−1. Rapid hydrolysis of β-CM7 in the apical chamber by the Caco-2 cells produced three
peptide metabolites: YP, GPI and FPGPI. All of these metabolites were detected in the basolateral
chamber after 30 min with both the YP and GPI peptides transporting at a higher rate than intact β-CM7.
In vitro satiety was indicated by the secretion of cholecystokinin [26–33] (CCK-8) and glucagon-like
peptide 1 (GLP-17–36NH2) in the STC-1 enteroendocrine cell model. CCK-8 secretion was highest in
response to β-CM7 followed by the β-CM7 metabolite FPGPI. CCK-8 secretion however was not signiﬁ-
cantly stimulated by the tri- or dipeptides. Secretion of GLP-1 was not signiﬁcantly stimulated by β-CM7
or YL. These in vitro results suggest that dairy peptide size enhances CCK-8 secretion, whilst limiting
transport across Caco-2 monolayers.
Introduction
Bovine milk is a source of biologically active peptides pro-
duced by the gastrointestinal digestion of milk proteins.1,2
Milk peptides have been found to exhibit various bioactivities
including antithrombotic, antioxidant, antihypertensive, anti-
microbial, immunomodulatory, anticarcinogenic, opioid and
mineral-carrying activities,3–7 as such these peptides have been
linked to a myriad of beneficial health outcomes including
improved clinical outcomes in cancer patients,8 reducing
cardiovascular risk and disease,5 improved digestive function,
nutrient absorption and growth and development of organs.9
Within bovine milk, caseins are by far the most abundant
group of proteins and are comprised of αS1-, αS2-, β- and
κ-caseins. Digestion of β-casein produces one of the best
known groups of food derived opioid peptides referred to as
β-casomorphins. The whey protein group is more diverse
comprised of β-lactoglobulin (β-Lg), α-lactoalbumin, immuno-
globin and several other proteins. β-Lg is the most abundant
whey protein and is also an important source of bioactive pep-
tides with gastrointestinal digestion producing a variety of
opioid peptides.10
β-Casomorphin-7 (YPFPGPI, β-CM7) represents β-casein
[60–66] and is one of the most well known β-casomorphins
due to its diverse biological activities and high resistance to
enzymatic degradation.11 The numerous biological activities
reported to be associated with β-CM7 reveal a dichotomous
nature. Apart from its strong opioid activity,12,13 β-CM7 has
been reported to provide a protective eﬀect in diabetes
through the reduced absorption of glucose and a reduction in
oxidative stress.14 However, other studies implicate β-CM7 in
the aetiology of human diseases like cardiovascular disease,
type 1 diabetes and sudden infant death syndrome.15 β-CM7 is†Electronic supplementary information (ESI) available. See DOI: 10.1039/c4fo00164h
aCSIRO Animal, Food and Health Sciences, 306 Carmody Road, St Lucia, QLD 4067,
Australia. E-mail: Simone.Osborne@csiro.au; Fax: +61-732142900;
Tel: +61-732142274
bCSIRO Animal, Food and Health Sciences, 671 Sneydes Road, Werribee, VIC 3030,
Australia
cCSIRO Animal, Food and Health Sciences, Gate 13 Kintore Avenue, Adelaide,
SA 5000, Australia




















































































View Journal  | View Issue
also the key diﬀerence in the peptide profile following the
gastrointestinal digestion of A1 milk compared to A2 milk.16,17
Thirteen genetic variants of the β-casein gene exist in dairy
cattle breeds world-wide, however A1 and A2 are the most
common variants giving rise to A1 and A2 milk.15 A single
amino acid substitution at position 67 from a proline in A1
β-casein, to a histidine in A2 β-casein, influences the enzymatic
digestion of A1 and A2 milk and subsequent release of the
β-CM7 peptide. Enzymatic digestion of A1 milk using pepsin,
trypsin and elastase releases four to ten-fold higher levels of
β-CM7 compared to the same enzymatic digestion of A2 milk.16,17
The precise biological activity of β-CM7 is complicated by the
lack of detection of intact bovine β-CM7 in adult human
plasma. To date, intact β-CM7 has not been detected in adult
human plasma following the ingestion of bovine milk or other
casein containing dairy products, however it has been found in
the jejunum of healthy adult subjects (aged 18–30) following
the ingestion of bovine casein,11 and in the plasma of infants
(under 1 year) following ingestion of formula containing bovine
milk.18 Animal studies involving adult and infant beagles investi-
gated the plasma levels of intact β-CM7 following ingestion of
bovine (casein based) milk.19 Quantifiable levels of intact
β-CM7 were only present in blood plasma from infant beagles,
with intact β-CM7 not detected in adult beagles. Therefore it is
unknown whether intact β-CM7 persists beyond the adult
intestinal epithelial in vivo. A recent review on the potential
health impact of β-casomorphins and related peptides,20 con-
cluded that the presence of intact β-casomorphin molecules in
blood after intake of milk or casein has not been established
in vivo as such there is no quantitative data on the absorption
of intact bioactive peptides for adults, except in the case for di-
and tripeptides with reported antihypertensive properties.
In vitro studies involving the Caco-2 transwell model of the
intestinal epithelium have revealed transport of intact β-CM7
with low permeability rates.21,22 In these studies rapid hydro-
lysis of β-CM7 over 60 min was observed and linked with the
action of dipeptidyl peptidase IV.21,22 It is possible that brush
border enzymes, including dipeptidyl peptidase IV, are respon-
sible for rapid degradation of β-CM7 that survives gastrointesti-
nal digestion preventing intact β-CM7 from being detected in
adult human plasma. It is likely that smaller peptides pro-
duced from the hydrolysis of β-CM7, rather than intact β-CM7,
are preferentially absorbed across the intestinal epithelium.
Bioactive dairy peptides are not only released by gastro-
intestinal digestion following consumption of dairy foods, but
are also generated during dairy processing and are therefore
present in products including milk protein hydrolysates,
fermented milk, yoghurt and cheese.23,24 Food products sup-
plemented with milk protein-derived bioactive peptides have
also been manufactured and have gained market interest.
Consumption of dairy products is associated with increased
satiety25–27 as well as a decreased prevalence of metabolic dis-
orders like obesity and type 2 diabetes.2,28 Amongst dairy pro-
teins there is evidence demonstrating the satiating eﬀects
of whey and casein proteins.26 Understanding the digestive
behaviour of dairy proteins and transport mechanisms of
resulting peptides may help to develop dairy based foods with
targeted health outcomes.
Satiety is influenced by a complex network of postprandial
gastrointestinal hormones secreted by enteroendocrine cells in
response to changes in the gut lumen.29 Cholecystokinin
(CCK) is a gut–brain peptide predominantly secreted by entero-
endocrine I cells in the small intestine in response to dietary
peptides and fatty acids, regulating gall bladder contraction,
pancreatic enzyme secretion, gastric emptying and appetite.30
The term CCK refers to a family of peptide hormones that are
the result of post-translational modifications to pro-CCK into
several diﬀerently sized peptides including CCK-8, CCK-33 and
CCK-58.31 In vivo CCK-8 [26–33] is one bioactive form of CCK
linked to satiety. In vitro STC-1 cells mainly process pro-CCK
into CCK-8,32 as such CCK-8 is secreted by STC-1 cells and rou-
tinely used to indicate satiety. Extensive research on CCK has
firmly established this hormone as a feed suppressive
peptide.33 Thus, CCK is an important regulator of ingestion,
digestion and nutrient absorption and a useful indicator of
satiety in vivo and in vitro.
In vitro studies have shown that protein hydrolysates,34 pep-
tides35,36 and amino acids37 induce CCK-8 secretion in the
STC-1 mouse enteroendocrine cell line as well as in CHO
(Chinese hamster ovary) cells38 stably transfected to express
the CCK-A receptor.39 The eﬀect of bovine β-CM7 or the β-Lg
dipeptide on CCK secretion in vitro or in vivo is unknown;
however several in vivo studies report conflicting findings in
terms of the eﬀect of β-casomorphins on feed intake and
satiety. Some animal studies report that administration of
β-casomorphins increases feed intake,40–42 whilst other studies
suggest that β-casomorphins present in casein hydrolysates
prolong gastrointestinal transit and delay gastric emptying43
through CCK-A receptors and opioid receptors.44–46 Further-
more, an in vitro study involving HEK293A human embryonic
kidney cells transfected with two isoforms of the 5-HT2C (sero-
tonin) receptors, demonstrated receptor agonist activity in
response to casein hydrolysate fractions suggesting casein pep-
tides, including β-casomorphins, may be involved in the regu-
lation of food intake and the suppression of appetite through
serotonin receptors.47 Conversely, radioreceptor analysis indi-
cated that both human and bovine β-CM7 act as 5-HT2C antag-
onists,48 suggesting a stimulatory role for these peptides. The
eﬀect of β-Lg on satiety is also unclear, however many studies
report the satiating eﬀect of whey protein49,50 with one recent
study implicating a role for β-Lg51 in satiety. Therefore, investi-
gating the eﬀect of β-CM7 and the β-Lg dipeptide on the
secretion of CCK-8 in vitro might help to gain insights into the
physiological eﬀect of these peptides.
Glucagon-like peptide 1 (GLP-1) is another gastrointestinal
hormone secreted by enteroendocrine cells in response to
changes in the gut lumen. GLP-1, produced by intestinal
L-cells in response to dietary carbohydrates, fatty acids and
peptides, is an incretin hormone involved in glucose-depen-
dent insulin release, attenuation of blood sugar, deceleration
of gastric emptying, acid secretion and food intake.52 GLP-1
exists in two biologically active forms produced by the
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post-translational modification of the proglucagon precursor
into the non-amidated GLP-17–37 and amidated GLP-17–36NH2.
In humans GLP-1 is eﬃciently amidated (>80%), however fol-
lowing intestinal secretion GLP-17–36NH2 is rapidly degraded by
dipeptidyl peptidase IV (DPPIV) producing GLP-19–36NH2.
53
In vitro, both of these forms are secreted by the STC-1 mouse
enteroendocrine cell line, with the amidated form also being
the most abundant.54 In vitro studies have shown that β-casein
stimulates GLP-1 secretion by STC-155 and other cells,56
however it is unknown whether β-CM7 or the β-Lg dipeptide
stimulate GLP-1 in vitro.
In this present work the in vitro transport and satiety of
bovine β-CM7 and a dipeptide derived from β-Lg were investi-
gated in an eﬀort to understand the fate and biological activity
of these peptides during intestinal absorption. Caco-2 cell
monolayers grown on transwell membranes were used to
model the intestinal epithelium for transport studies, whilst
CCK-8 and GLP-1 secretion by the mouse enteroendocrine
STC-1 cell line was used as an indicator of satiety.
Materials and methods
Cell culture media and reagents
The Caco-2 (human colorectal adenocarcinoma) cell line was
purchased from the American Type Culture Collection (ATCC).
The STC-1 (mouse enteroendocrine) cell line was secured from
the safe deposit section of ATCC (via Dr Douglas Hanahan).
Dulbecco’s modified eagle’s medium (DMEM) with high
glucose (4500 mg mL−1), heat inactivated fetal bovine serum
(FBS), nonessential amino acids (NEAA), Hank’s balanced salt
solutions (HBSS), phosphate buﬀered saline (PBS), rhodamine
phalloidin, TO-PRO®3 and penicillin/streptomycin were pur-
chased from Gibco/Life Technologies. Transwells with poly-
carbonate membranes (0.4 μm pore size; surface area 0.33 cm2)
were from Corning. Cell culture flasks and 96 well plates
were from Nunc. The CellTiter 96® AQueous non-radioactive
cell proliferation assay (MTS) cell viability assay was from
Promega. Bovine β-CM7 (YPFPGPI), β-Lg (YL) dipeptide
and β-CM7 (YP) dipeptide were from Bachem. The β-CM7
metabolites GPI and FPGPI were synthesised by AusPep. The
cholecystokinin [26–33] (CCK-8), non-sulphated (human,
rat, mouse) fluorescent EIA kits and bombesin were from
Phoenix Pharmaceuticals Inc (Burlingamed, USA). The HPLC
reagents included triflouroacetic (TFA) acid from Sigma and
acetonitrile (ACN) from Merck. LC-MS reagents included
formic acid (FA) from Ajax Finechem Pty Ltd and acetonitrile
from RCI Labscan Ltd. The MALDI-TOF reagents, including
2-cyano-4-hydroxy-cinnamic-acid (CHCA) and Peptide Cali-
bration Standard II (PepCal II), were purchased from Bruker
(Billerica, USA).
Determination of dairy peptide toxicity
Cell viability in response to the dairy peptides was evaluated
prior to and following the Caco-2 transwell experiments, and
following the STC-1 secretion assays using MTS assays.
For the Caco-2 cells, cell viability in response 31.25–2000 μM
peptide concentration was established using 1 × 104 Caco-2
cells per well grown in a 96 well plate for 7 days. On day 7,
growth media was removed and replaced with HBSS containing
peptides for 60 min. The Caco-2 cells were then washed once
in HBSS and assayed using 100 μL HBSS with 20 μL MTS
reagents. Following a 2 h 37 °C/5% CO2 incubation, absor-
bance at 485 nm indicated cell viability. Cell viability was
also monitored following the transport experiments by measuring
pre- and post-transepithelial electrical resistance readings (TEER).
For the STC-1 cells, cell viability was assessed following col-
lection of the CCK-8 and GLP-1 containing cell supernatants.
The cells were assayed using 100 μL HBSS with 20 μL MTS
reagents. Following a 2 h 37 °C/5% CO2 incubation, absor-
bance at 485 nm indicated cell viability.
Caco-2 cell and STC-1 culture
The Caco-2 cells were routinely cultured in DMEM sup-
plemented with 10% FBS, 1% w/v penicillin/streptomycin and
1% w/v NEAA. The STC-1 cells were cultured in DMEM sup-
plemented with 10% FBS, 1% w/v penicillin/streptomycin and
1% w/v Glutamax. All cells were grown at 37 °C in a humidified
atmosphere with 5% CO2. For experimentation all cells were
maintained between passages 5–20.
Caco-2 cell monolayer culture on transwells and peptide transport
The Caco-2 cells were seeded into transwell apparatus at a cell
density of 1.2 × 105 cells cm−2 and cultured in growth media
for 21 days to facilitate cell diﬀerentiation and formation of an
intact monolayer. During the 21 day diﬀerentiation period,
growth media was removed and replaced with fresh media every
2–3 days. Cell diﬀerentiation and formation of an intact mono-
layer was monitored by measuring the transepithelial electrical
resistance (TEER) of the cell monolayer in an apical – basolateral
direction. TEER was measured using a Millicell-ERS Voltohm-
meter (Millipore) with values above 0.35 kΩ cm−2 indicative of
diﬀerentiated Caco-2 cells and an intact monolayer.22,57,58
Formation of an intact monolayer was also visualised using
confocal microscopy by fixing the Caco-2 cells to the transwell
membrane and staining with fluorescent dyes. At day 21, the
cells were washed, fixed57 and stained with rhodamine phalloi-
din and TO-PRO®3 to visualise the tight junctions and nuclei
(respectively). Confocal microscopy was performed on a Leica
TCS SP5 confocal laser scanning microscope (Leica 143 Micro-
systems, Wetzlar, Germany) using a 100× oil immersion objec-
tive. To image the tight junctions (stained with rhodamine
phalloidin) a 543 nm laser was used and bandwidth of
564–699 nm collected. To image the cell nuclei (TO-PRO®3) a
488 nm laser was used and bandwidth of 494–527 nm collected.
On the day of transport TEER was measured and growth
media replaced with HBSS in the apical and basolateral
chambers for 4 h to enhance uptake of exogenous peptides.
For dairy peptide transport, 200 μL of 500, 1000 and 2000 μM
β-CM7 and YL in HBSS were applied to the apical chamber for
30 min. HBSS (600 μL) was also replaced in the basolateral
prior to transport. After 30 min all apical and basolateral
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transport samples were collected and stored at −80 °C. HBSS
was replaced in all chambers with TEER values measured
again. Transport studies were performed in duplicate with six
replicates (n = 12). The rate of peptide transport across the
transwell membrane was determined by calculating the appar-
ent permeability coeﬃcient (Papp) as previously described
59
and as follows: (ΔQ/Δt ) × (1/A × 1/C0). Where ΔQ is the change
in peptide concentration in the basolateral chamber (μmoles);
Δt is the transport time (seconds); A is the surface area of the
transwell membrane (cm2) and C0 is the initial concentration
of peptides applied to the apical chamber (μmoles mL−1). Papp
is measured in cm s−1.
Multiple reaction monitoring (MRM) of intact peptides in
apical and basolateral samples
Ultra high performance liquid chromatography (UHPLC, Shi-
madzu) coupled to a 4000 QTRAP LC-MS/MS system (AB/Sciex,
Foster City, USA) was used for quantification of the β-Lg YL
dipeptide and the various forms of β-CM7, including the intact
peptide (YPFPGPI) and its metabolites (YP, GPI and FPGPI), in
the Caco-2 transwell transport samples. Peptide separation was
achieved using a Kinetex 1.7 μm C18 100 Å (100 × 2.1 mm)
column from Phenomenex with a flow rate of 0.4 mL min−1
using a linear gradient of 5–45% buﬀer B over 10 minutes.
Buﬀer A consisted of 0.1% v/v FA in MilliQ water and buﬀer B
consisted of 0.1% v/v FA and 90% v/v ACN in MilliQ water. The
column oven temperature was 60 °C. The total run time was
15 min and an injection volume of 2 μL was used. The MS
parameters were as follows: curtain gas 35; ion spray voltage
5300 V, temperature 500 °C, ion source gas 1 and 2 both set to
50. All transport samples were diluted in 0.1% v/v FA. Four
sets of peptide standards containing: 0.0025–10 μM β-Lg YL
dipeptide (12 concentrations); 0.05–50 μM β-CM7 (10 concen-
trations); 0.05–25 μM YP (9 concentrations); 0.05–10 μM GPI (8
concentrations) and 0.005–2.5 FPGPI μM (9 concentrations)
were used to calculate unknown peptide concentrations in the
apical and basolateral transport samples. Linear regression
analysis of log10 transformed data was performed in GraphPad
Prism v6. The following liner regression equations were used
to calculate the unknowns for each peptide analysed:
(1) β-Lg YL = 0.9735x + 6.480 (r2 = 0.9984).
(2) β-CM7 = 1.833x + 4.897 (r2 = 0.9653; low range standards
for basolateral samples 0.05–2.5 μM) and 1.019x + 5.243 (r2 =
0.9753; high range standards for apical samples 1.0–50 μM).
(3) β-CM7 metabolite YP = 0.9344x + 5.416 (r2 = 0.9984).
(4) β-CM7 metabolite GPI = 0.9203x + 5.237 (r2 = 0.9972).
(5) β-CM7 metabolite FPGPI = 0.9441x + 6.263 (r2 = 0.9974).
Reverse phase high performance chromatography (RP-HPLC)
and matrix-assisted laser desorption ionisation time-of-flight/
time-of-flight (MALDI-TOF/TOF) analysis
To identify apical and basolateral peptides, the transport
samples were separated using RP-HPLC with a 250 × 2.1 mm,
300 Å, 5 μm C18 reverse phase column (Everest, Grace Davison
Discovery Sciences). The flow rate was 0.15 mL min−1 with
buﬀer A 0.1% v/v TFA in MilliQ water, and buﬀer B 0.1%
v/v TFA in ACN. A linear gradient of 5–60% buﬀer B over
65 minutes was employed. The column compartment tempera-
ture was 25 °C. Fractions were collected and dried by vacuum
concentration. For MALDI-TOF/TOF mass spectrometry, solu-
tions were lyophilised and reconstituted in 20 μL of 0.1%
trifluoroacetic acid and analysed by matrix-assisted laser de-
sorption/ionization (MALDI) on an UltrafleXtreme tandem time
of flight (TOF/TOF) MS (Bruker Daltonics, Bremen, Germany).
The sample (1 μL) was mixed 1 : 1 with CHCA (7.5 mg mL−1 in
70% acetonitrile, 0.1% TFA, 1 mM ammonium phosphate) and
1 μL spotted directly onto a polished steel MALDI target. Data
were acquired in positive ion reflector mode over the mass
range 100–1000 Da using the FlexControl software. The laser
power was set to 30% and 2000 shots were averaged for MS
acquisition. Tandem MS spectra were acquired automatically
with 2000 shots averaged per spectra.
CCK-8 and GLP-1 secretion by STC-1 cells
STC-1 cells per well were seeded into 96 well plates (1 × 105
cells per well) in phenol red-free, DMEM growth media and
incubated for 24 h at 37 °C/5% CO2. Following the 24 hour
incubation, growth media was replaced with phenol red-free
and serum-free DMEM and incubated for 3 h at 37 °C/5%
CO2. Following the 3 hour incubation, 100 μL of HBSS con-
taining diﬀerent peptides were added to the cells for 2 h at
37 °C/5% CO2. Bombesin (100 μM) and a commercial whey
hydrolysate (1 mg mL−1) were used as positive controls for
CCK-8 secretion and GLP-1 secretion. HBSS was used as the
negative control for both CCK-8 and GLP-1 secretion. Cell
supernatants were collected after the 3 hour incubation and
stored at −80 °C until required. Cell viability was measured
immediately after the assay as detailed above. Cholecysto-
kinin 26–33 (CCK-8) and glucagon-like peptide 1 7–36 amide
(GLP-17–36NH2) was measured in the supernatants using the
CCK-8, non-sulphated (human, rat, mouse) and GLP-17–36NH2
fluorescent EIA kits (Phoenix Pharmaceuticals Inc). Assays
were performed in triplicate and expressed as ratio to basal
(HBSS) secretion.
Statistical analysis
All statistical analyses were conducted using a one-way ANOVA
followed by post hoc comparisons using Tukey’s or Dunnett’s
multiple comparisons test. p-values less than 0.05 were con-
sidered significant. These calculations were performed using
GraphPad Prism 6 Software for Windows (GraphPad Software,
San Diego California USA, http://www.graphpad.com).
Results
In vitro transport of intact β-CM7 and β-Lg dipeptide (YL)
To investigate the fate of β-CM7 and dipeptide YL during intes-
tinal absorption, the Caco-2 transwell model of the small intes-
tine was used to measure in vitro transport and hydrolysis
of 500, 1000 and 2000 μM β-CM7 and YL. Toxicity of these
concentrations was assessed prior to transport using a cell
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viability assay. No significant changes to cell viability were
observed at any of the peptide concentrations. Additionally,
TEER values were measured before and after transport and
remained above 0.35 kΩ cm−2 indicating Caco-2 cell viability
and an intact monolayer. Confocal images of fixed and stained
Caco-2 cell monolayers grown on transwell membranes indica-
tive of TEER values >0.35 kΩ cm−2 are shown in Fig. 1. For
transport of 500, 1000 and 2000 μM β-CM7, the average TEER
values were 0.85, 0.78 and 0.78 kΩ cm−2 before transport, and
0.61, 0.6 and 0.73 kΩ cm−2 immediately after transport,
respectively. For transport of 500, 1000 and 2000 μM LY, the
average TEER values were 0.80, 0.83 and 0.96 kΩ cm−2 before
transport and 0.58, 0.72 and 0.75 kΩ cm−2 immediately after
transport, respectively.
To promote uptake and transport of the peptides across the
Caco-2 cell monolayers, serum peptides were depleted by incu-
bating the Caco-2 cells in HBSS for 4 h prior to transport (as
previously described60,61). Hydrolysis and transport of intact
β-CM7 and YL after 30 min was determined by measuring the
peptide concentrations in the apical and basolateral chambers
using multiple reaction monitoring mass spectrometry
(MRM-MS). Apical concentrations of YL did not significantly
change following transport with only slight decreases in
peptide concentration following application of 1000 and
2000 μM YL (Fig. 2A). The apical concentration of β-CM7
decreased significantly by 82%, 53% and 23% following appli-
cation of 500, 1000 and 2000 μM β-CM7, respectively (Fig. 2A).
Intact YL was quantified in all basolateral samples by
MRM-MS, however intact β-CM7 was only detected at the
highest concentration (Fig. 2B).
Basolateral peptide concentrations were used to calculate
transport rates (Table 1) with the highest rate observed for
1000 μM YL, however there were no significant diﬀerences in
transport rate following application of 1000 and 2000 μM YL.
Transport rate of β-CM7 could only be calculated following
application of 2000 μM β-CM7. The significantly lower levels of
β-CM7 remaining in the apical samples (compared to β-Lg), in
conjunction with the absence of β-CM7 in the basolateral
samples, indicated hydrolysis of β-CM7 by the Caco-2 cells.
In vitro hydrolysis of β-CM7 and identification of
β-CM7 metabolites
To further investigate the fate of β-CM7 during intestinal
absorption and explain the significant decrease in apical con-
centrations that did not correlate with transport rate, apical
and basolateral samples following 2000 μM β-CM7 were ana-
lysed by RP-HPLC. Several additional peaks were observed in
the apical (Fig. 3A) and basolateral (Fig. 3B) transport chromato-
grams and were compared to a β-CM7 RP-HPLC standard
(Fig. 3C) and HBSS control apical (Fig. 3D) and basolateral
(Fig. 3E) samples obtained following transport of HBSS only.
These comparisons revealed the presence of intact β-CM7
Fig. 1 Caco-2 cell monolayers grown on transwell membranes for 21
days (with TEER values >0.35 kΩ cm−2) imaged using confocal
microscopy. Nucleic acids and tight junctions visualised in blue
(TO-PRO®3) and red (rhodamine phalloidin) ﬂuorescence respectively.
Fig. 2 Concentration of intact β-CM7 and YL in apical (A) and basolateral (B) chambers after 30 min in vitro transport determined by MRM-MS.
Results are expressed as the mean (±standard error) of duplicate experiments conducted in replicates of six (n = 12). Data with diﬀerent letters a and
b display signiﬁcant statistical diﬀerences (one way ANOVA with Tukey multiple comparisons, p < 0.05).
Table 1 Comparison of β-CM7 and YL transport rates through Caco-2







500 μM ND 0.37 ± 0.04a
1000 μM ND 5.26 ± 1.51b
2000 μM 0.13 ± 0.002a 3.28 ± 0.74b
aData expressed as the mean ± standard error of duplicate
experiments conducted in replicates of six (n = 12). Data with diﬀerent
letters a and b display significant statistical diﬀerences (one way
ANOVA with Tukey multiple comparisons, p < 0.05). bND β-CM7 not
detected in MRM-MS analyses.
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Fig. 3 RP-HPLC chromatograms and numbered peaks selected for MALDI-TOF MS analysis from a 30 min in vitro transport of 2000 μM β-CM7 and
HBSS using Caco-2 monolayers. Chromatograms are representative of: (A) 2000 μM β-CM7 apical transport sample; (B) 2000 μM β-CM7 basolateral
transport sample; (C) 1000 μM β-CM7 RP-HPLC standard; (D) HBSS control apical sample; and (E) HBSS control basolateral sample.
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along with several distinguishable peaks. RP-HPLC fractions
containing intact β-CM7 and several other peaks were selected
for identification by MALDI-TOF MS analysis. In total, eight
diﬀerent fractions were chosen from duplicate 2000 μM β-CM7
apical and basolateral transport samples.
MALDI-TOF analysis revealed the presence of intact β-CM7
and fragments of β-CM7 along with two unknown peaks.
The masses in the spectra from fractions 1–4 collected from
the 2000 μM β-CM7 apical sample (Fig. 3A) correlated with the
masses for intact β-CM7 (YPFPGPI) and the three β-CM7 frag-
ments YP, GPI and FPGPI (ESI† and Table 2). The masses from
fractions 6 and 8 collected from the 2000 μM β-CM7 basolat-
eral sample (Fig. 3B) correlated with the masses for YP and
intact β-CM7 (YPFPGPI). Peptide sequences were also con-
firmed for all β-CM7 fragments by MS/MS. No peptide peaks
were identified by MALDI-TOF MS in samples 5 and 7. This
confirmed transport of intact β-CM7 whilst identifying three
β-CM7 metabolites in apical samples. Of the three metabolites,
YP was identified in the basolateral samples confirming its
transport. To determine if the FPGPI or GPI metabolites were
transported, RP-HPLC was used to compare each β-CM7 apical
(Fig. 4) and basolateral transport sample (Fig. 5) indicating the
presence of FPGPI and GPI fragments in the basolateral
samples. On the basis of the MALDI-TOF MS spectra and on
the common peaks in the RP-HPLC chromatograms, it was
assumed that FPGPI and GPI were also transported into the
basolateral samples. Synthetic YP, GPI and FPGPI peptides
were then used to construct standard curves for MRM-MS to
quantitate the levels of β-CM7 metabolites in all apical and
basolateral samples.
In vitro transport of β-CM7 metabolites
Apical and basolateral concentrations of the β-CM7 metabolites
YP, GPI and FPGPI were measured by MRM-MS revealing sig-
nificant diﬀerences between the appearance of these metab-
olites in the apical samples and transport across the Caco-
2 monolayer. In the apical samples the dipeptide YP was the
most abundant metabolite across all β-CM7 transport con-
centrations (Fig. 6A), however no significant diﬀerence in YP
concentration was observed between the 1000 and 2000 μM
β-CM7 transport concentrations. The next most abundant
metabolite was the tripeptide GPI following the same trend as
YP. The pentapeptide FPGPI was the least abundant
β-CM7 metabolite in all apical samples, however it did increase
significantly with β-CM7 transport concentrations. The baso-
lateral β-CM7 metabolite concentrations followed the same
trends to those observed in the apical samples (Fig. 6B) with
the dipeptide YP concentration being significantly higher than
GPI and FPGPI at both the 1000 and 2000 μM transport con-
centrations. Again the pentapeptide FPGPI was the least abun-
dant metabolite, with no significant increase across the β-CM7
transport concentrations.
The transport rate of each β-CM7 metabolite was calculated
using the initial concentration of β-CM7 in the apical chamber
(Table 3). Accordingly, the most permeable metabolite was YP
with a transport rate of 0.35 × 10−6 cm s−1 following transport
of 2000 μM β-CM7. The tripeptide GPI was the next most per-
meable metabolite with a transport rate of 0.28 × 10−6 cm s−1
following transport of 2000 μM β-CM7. The transport rate of
FPGPI however remained low at 0.02 × 10−6 cm s−1 and did not
significantly change across the increasing β-CM7 transport
concentrations.
In vitro satiety of selected dairy peptides
To investigate the in vitro satiety of β-CM7 and YL during intes-
tinal absorption, the STC-1 mouse enteroendocrine cell line
was used to measure in vitro satiety through the secretion of
CCK-8 and GLP-1 in response to 1000, 500, 250 and 125 μM YL
and β-CM7. Serum peptides were depleted by incubating the
STC-1 cells in phenol red free and serum free DMEM for 3 h
prior to application of the dairy peptides. Toxicity of these
peptide concentrations was assessed following each experi-
ment using a cell viability assay. No significant cell toxicity
was observed following any of the peptide concentrations.
Secretion of GLP-1 was not stimulated by YL or β-CM7 (Fig. 7)
however CCK secretion significantly increased in response to
all β-CM7 treatments (Fig. 8). To further investigate the CCK
response to β-CM7, secretion of CCK was measured following
application of the β-CM7 metabolites YP, GPI and FPGPI
(Fig. 9). The amount of CCK-8 secretion in response to GPI
and YP were similar and not significantly above basal levels,
however a significant increase in CCK-8 secretion was observed
following treatment with 1000 μM FPGPI.
Discussion
The results from this study confirm the low in vitro transport
rates and rapid hydrolysis of bovine β-CM7 (YPFPGPI) pre-
viously observed in studies involving the Caco-2 transwell
model of the intestinal epithelium.21,22 Furthermore, this
study revealed the outcomes of the in vitro hydrolysis in terms
of three newly identified β-CM7 peptide metabolites FPGPI
(62–66), GPI (64–66) and YP (60–61). The concentration of the
three peptide fragments accounted for the decrease in apical
β-CM7 concentration observed after 30 min in vitro. The resulting
Table 2 Peptides identiﬁed by RP-HPLC/MALDI-TOF MS in β-CM7







Fraction 1 (apical) 279.3 YP
Fraction 2 (apical) 286.5 GPI
Fraction 3 (apical) 530.3 FPGPI
Fraction 4 (apical) 790.4 YPFPGPI
Fraction 5 (basolateral) No unique
peaksa
—
Fraction 6 (basolateral) 279.3 YP
Fraction 7 (basolateral) No unique
peaksa
—
Fraction 8 (basolateral) 790.4 YPFPGPI
aNo unique peaks were identified in MALDI-TOF MS spectra.
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Fig. 4 RP-HPLC chromatograms and MALDI-TOF MS identiﬁed peaks from β-CM7 apical and HBSS control transport samples following a 30 min
in vitro transport using Caco-2 monolayers. Chromatograms are representative of typical apical transport samples from (A) 2000 μM β-CM7;
(B) 1000 μM β-CM7; (C) 500 μM β-CM7; and (D) HBSS only. Asterisks * denotes inferred amino acid sequences.
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Fig. 5 RP-HPLC chromatograms and MALDI-TOF MS identiﬁed peaks from β-CM7 basolateral and HBSS control transport samples following a
30 min in vitro transport using Caco-2 monolayers. Chromatograms are representative of typical basolateral transport samples from (A) 2000 μM
β-CM7; (B) 1000 μM β-CM7; (C) 500 μM β-CM7 and (D) HBSS only. ● indicates peaks common to HBSS control transport basolateral samples.
Asterisks * denotes inferred amino acid sequences.
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peptide fragments suggest the action of the brush border
hydrolase, dipeptidyl peptidase IV (DPPIV), due to the liber-
ation of X–P dipeptides from the N-terminus,62 however future
experiments involving DPPIV antagonists are needed to
confirm this. The in vivo functions of DPPIV have not been
fully elucidated however it is known to play a key role in the
hydrolysis and inactivation of numerous peptides, including
β-CM7. The levels and enzyme activity of DPPIV have pre-
viously been measured in Caco-2 cells and correlate with a
diﬀerentiated phenotype.63 In recent Caco-2 studies, the
DPPIV inhibitor diprotin was used to block hydrolysis and
enhance uptake of β-CM7.22
Fig. 6 Concentrations of β-CM7 metabolites YP , GPI and FPGPI , after in vitro transport in apical (A) and basolateral (B) transport samples.
Metabolites were measured in apical and basolateral chambers after 30 min using MRM-MS. Results are expressed as the mean (±standard error) of
duplicate experiments conducted in replicates of six (n = 12). Data with diﬀerent letters display signiﬁcant statistical diﬀerences (one way ANOVA
with Tukey multiple comparisons, p < 0.05).











500 0.18 ± 0.03ab 0.11 ± 0.02bc 0.02 ± 0.002c
1000 0.32 ± 0.03de 0.22 ± 0.02be 0.02 ± 0.001c
2000 0.35 ± 0.05d 0.28 ± 0.03ade 0.03 ± 0.004c
aData expressed as the mean ± standard error of duplicate experiments conducted in replicates of six (n = 12). Data with diﬀerent letters a and b
display significant statistical diﬀerences (one way ANOVA with Tukey multiple comparisons, p < 0.05).
Fig. 7 Secretion of glucagon-like peptide 1 (GLP-1) by STC-1 cells in
response to decreasing concentrations of YL and β-CM7 , compared
to HBSS control . Results are expressed as a ratio to basal GLP-1
secretion represented as the mean ± standard error. Assay was per-
formed in triplicate (n = 3). No signiﬁcant diﬀerences were observed
between the data sets (statistical diﬀerences determined using a one
way ANOVA with Dunnett’s multiple comparisons to HBSS (basal)
control, p < 0.05).
Fig. 8 Secretion of cholecystokinin [26–33] (CCK-8) by STC-1 cells in
response to decreasing concentrations of YL and β-CM7 , compared
to HBSS (basal) control . Results are expressed as a ratio to basal
CCK-8 secretion represented as the mean ± standard error. Assay was
performed in triplicate (n = 3). Data with * displays signiﬁcant secretion
of CCK-8 above HBSS (basal) levels (statistical diﬀerences determined
using one way ANOVA with Dunnett’s multiple comparisons to HBSS
(basal) control, p < 0.05).
Food & Function Paper




















































































It is suggested that the action of Caco-2 DPPIV facilitated
the hydrolysis of β-CM7 observed in this study, however the
resulting decrease in β-CM7 apical concentrations may not
have been the only factor limiting transport of intact β-CM7
across the Caco-2 monolayer. Recently two oligopeptide trans-
porters were identified in Caco-2 cells, sodium-coupled oligo-
peptide transporters 1 and 2 (SOPT1 and SOPT2).64 These
transporters accept oligopeptides consisting of five or more
amino acids and are inhibited by the presence of di- and tri-
peptides. Studies in retinal and neuronal cells suggest that
opioid peptides are preferentially transported through
SOPT2.65,66 The production of β-CM7 metabolites YP and GPI
in the apical chamber may limit Caco-2 transport of intact
β-CM7 through inhibition of SOPT2-mediated transport. Simi-
larly, this could account for the very low transport rates associ-
ated with permeability of the β-CM7 metabolite FPGPI.
However, further studies are required to elucidate the precise
transport mechanism involved in the in vitro permeability of
β-CM7.
In this study, transport of di- and tripeptides was signifi-
cantly higher than transport of larger oligopeptides. The
highest transport rates measured were following application of
1000 and 2000 μM β-Lg dipeptide YL. The transport rates of
the β-CM7 peptide metabolites YP and GPI were also 2–3 times
higher than the transport rate of intact β-CM7, and 5–15 times
higher than the β-CM7 metabolite FPGPI. Intestinal transport
of di- and tripeptides can occur through several mechanisms
including proton coupled membrane transporters like Peptide
Transporters 1 and 2 (PepT1 and PepT2), paracellular transport
and transcytosis.67 PepT1 is generally considered a degradative
pathway68 hydrolysing the di- and tripeptides into their con-
stituent amino acids. PepT1 is expressed in Caco-2 cells69 and
has been well characterised. The in vitro transport of the intact
tripeptide GPI observed in this study concurs with transport
previously reported for the tripeptides VPP70 and YPI67
suggesting a mechanism diﬀerent to PepT1. According to pre-
vious studies paracellular diﬀusion70 could be the transport
pathway preventing degradation of the peptides by intracellu-
lar peptidases. Alternatively the pathway may be intracellular
whereby GPI was resistant to the endogenous enzymes.
The concentration of β-Lg dipeptide YL in the apical and
basolateral chambers accounted for almost all of the dipeptide
initially applied to the apical chambers. Only 6% of β-Lg
dipeptide YL was unaccounted for following transport of
1000 μM β-Lg YL, otherwise it appeared as though the dipep-
tide remained intact throughout the 30 min in vitro transport.
This suggests YL may also transport paracellularly, or that it’s
not only resistant to DPPIV but also other intracellular
enzymes produced by Caco-2. Similarly the β-CM7 metabolite
YP also transported across Caco-2 monolayer intact – with no
apparent loss in β-CM7 concentration when the sum of all
detectable β-CM7 metabolites was considered. However it is
important to note that this investigation was not targeted to
individual amino acid analysis, therefore it is possible that
amino acids may have been released undetected. Regardless of
the di- and tripeptide transport routes YL, YP and GPI trans-
ported intact, indicating that these peptides may persist
beyond the intestinal epithelium in vivo.
In terms of biological activity of these peptides at the intes-
tinal epithelium, satiety (indicated by the secretion of CCK-8
and GLP-1 by STC-1 cells) was measured in response to the
β-Lg dipeptide YL, intact β-CM7 and its metabolites (YP, GPI
and FPGPI). No significant GLP-1 secretion was observed in
response to the β-Lg dipeptide YL or intact β-CM7. This is con-
sistent with previous in vitro studies where the application of
peptides, including β-CM7, to STC-1 cells did not induce
GLP-1 secretion above basal levels.71 Other in vitro studies
suggest that protein hydrolysates71 and larger peptides,35 as
well as alternative protein sources like meat and eggs, signifi-
cantly induce GLP-1 secretion.72 CCK-8 secretion however was
significantly induced in response to intact β-CM7 and its
metabolite FPGPI. No significant CCK secretion was observed
in response to the tri- or dipeptides, however a significant
decrease in CCK-8 secretion was observed following treatment
with 125 μM YL. Cell numbers were maintained during this
treatment, however decreased metabolic activity within the
cells may be the cause of the decreased CCK-8 secretion.
Future studies are required to confirm this observation.
The highest induction of CCK-8 secretion was observed in
response to intact β-CM7, followed by the β-CM7 metabolite
FPGPI. The levels of CCK-8 secretion induced by intact β-CM7
at all concentrations were comparable to 1 mg mL−1 commer-
cial whey hydrolysate (data not shown) suggesting that β-CM7
was as eﬀective at inducing CCK-8 secretion as a pool of
diﬀerent peptides. Additionally, recent studies have also
reported the STC-1 secretion of CCK-8 in response to a quadra-
peptide (IHRF)73 with a similar fold-induction to that observed
in this study in response to GPI and FPGPI. Previous studies
Fig. 9 Secretion of cholecystokinin [26–33] (CCK-8) by STC-1 cells in
response to decreasing concentrations of β-CM7 metabolites YP , GPI
and FPGPI , compared to HBSS (basal) control . Results are
expressed as a ratio to basal CCK-8 secretion represented as the mean
± standard error. Assay was performed in triplicate (n = 3). Data with *
displays signiﬁcant secretion of CCK-8 above HBSS (basal) levels (stat-
istical diﬀerences determined using one way ANOVAwith Dunnett’s mul-
tiple comparisons to HBSS (basal) control, p < 0.05).
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reported CCK-8 secretion in response to di- (RF)36 and tripep-
tides,37 however the concentrations of peptides applied to the
STC-1 cells were three to ten-fold higher than those applied in
this study. It is possible that higher non-toxic concentrations
of YL and YP might stimulate CCK-8 secretion above basal
levels.
Studies involving the siRNA inhibition of the heteromeric
amino acid (umami) taste receptor (T1R1–T1R3) in the STC-1
cell line indicate that T1R1–T1R3 acts as a luminal sensor for
F, L and E amino acid induced CCK-8 secretion.37 Other
studies involving calcium-sensing receptor (CaSR) linked
CCK-8 secretion in STC-1 cells provide further evidence of F as
an intraluminal CCK stimulator.74 These studies applied con-
siderably (five to fifty-fold) higher concentrations of amino
acids than the concentrations of peptides applied in this
study. However, in this study significant CCK-8 secretion was
induced in response to peptides containing F amino acids.
Thus further experiments are required to determine whether
peptide size, amino acid composition or concentration was the
determining factor in CCK-8 secretion by the STC-1 cells.
Conclusions
This study confirmed the relatively low transport and rapid
hydrolysis of β-CM7 by Caco-2 cells previously reported, and
has further revealed the outcome of this hydrolysis by identify-
ing three peptide β-CM7 metabolites. These previously unre-
ported β-CM7 peptides, YP, GPI and FPGPI, were found to
transport across the Caco-2 monolayer at variable rates and
diﬀerentially induce CCK-8 secretion by STC-1 cells. The YP
and GPI peptide metabolites transported at the highest rates,
however the longer FPGPI peptide metabolite induced the
most CCK-8 secretion. These in vitro results suggest that the
fate and low transport rate of β-CM7 at the intestinal epi-
thelium is most likely determined by brush border hydrolases
rather than limited transport routes, providing a possible
explanation for the lack of β-CM7 in adult blood and urine fol-
lowing consumption of casein. In summary, this study has
investigated the in vitro transport and satiety of dairy di-, tri-,
penta- and heptapeptides, indicating that peptide size limits
transport across Caco-2 monolayers, whilst enhancing CCK-8
secretion by STC-1 cells. Future studies are needed to investi-
gate the digestive behavior and fate of other dairy peptides at
the intestinal epithelium, so as to identify specific peptides
that may be useful for designing dairy products with enhanced
satiety and other targeted health outcomes.
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